ライフサイエンスコーパス: MCID

1 MCID estimates at 12 months were calculated in the poole

2 MCID was estimated using mean change scores of patients

3 study, we aimed to assess responsiveness and MCID of four outcome measures used in atopic eczema: the

4 d a minimum clinically important difference (MCID) as 1 standard error of measurement from a well-cha

5 the minimum clinically important difference (MCID) has not been established.

6 and minimal clinically important difference (MCID) have not been established.

7 the minimum clinically important difference (MCID) in HRQOL measures was assessed.

8 e minimally clinically important difference (MCID) in HRQOL scores in HCV.

9 The minimum clinically important difference (MCID) in score is 0.5.

10 f a minimal clinically important difference (MCID) is well established.

11 the minimal clinically important difference (MCID) of the POEM in young children with eczema.

12 and minimal clinically important difference (MCID) should be known.

13 Minimum clinically important difference (MCID) was also measured.

14 re (minimal clinically important difference [MCID] = 19 seconds) and proportion of patients improving

15 e]; minimal clinically important difference [MCID], 1.8 units) and physical function (Western Ontario

16 hs (minimal clinically important difference [MCID], 25 m).

17 us; minimum clinically important difference [MCID], 4 units).

18 t]; minimal clinically important difference [MCID], 9 points); and symptom burden translated to the E

19 he minimal clinically important differences (MCID) for FVC% predicted in the Scleroderma Lung Study I

20 [no difficulty] to 68 [extreme difficulty]; MCID, 6 units) at 12 weeks.

21 0.7 units), baseline 6-minute walk distance (MCID, 30 m), and exacerbation frequency (events per 100

22 C] scale 0 to 4; 4 represents worse dyspnea; MCID, 0.7 units), baseline 6-minute walk distance (MCID,

23 expiratory volume in the first second (FEV1; MCID, 10%).

24 for each of these subscales met criteria for MCID.

25 FVC% improvement by >/=MCID was associated with either statistically significan

26 PROs, QILD, and QLF, while FVC% worsening >/=MCID was associated with statistically significant or nu

27 sent molecular computational identification (MCID), a demonstration that molecular logic and computat

28 t in patients with HCV, and generated a mean MCID of 4.2 points on this scale.

29 We next assessed the association of MCID estimates for improvement and worsening of FVC% wit

30 oundID.org ), and a spectral search program, MCID MS/MS, has been developed to allow a user to search

31 his spectral library is hosted at the public MCID Web site ( www.MyCompoundID.org ), and a spectral s

32 g the St George's Respiratory Questionnaire (MCID, 4) and change in forced expiratory volume in the f

33 roke Impact Scale (SIS) hand function score (MCID = 17.8 points).

34 The MCID estimates for the pooled cohort at 12 months for FV

35 The MCID of the AE-QoL total score was found to be six point

36 The MCID of the POEM change score, in relation to a slight i

37 The MCID was 8.7 points for the SCORAD, 8.2 for the objectiv

38 on of patients who received CYC achieved the MCID compared with placebo in the HAQ DI score (30.9% ve

39 In addition, the MCID was determined using anchor-based and distributiona

40 ng children is responsive to change, and the MCID is around 3.

41 ter" or "somewhat worse" were defined as the MCID estimates.

42 ic curves consistently identifying -2 as the MCID.

43 Five methods of determining the MCID of the POEM were employed; three anchor-based metho

44 (half SD, SE of measurement) to estimate the MCID for the CAT; we included only patients with paired

45 a modified Delphi technique to estimate the MCID in HCV.

46 Distribution-based estimates for the MCID ranged from -3.3 to -3.8.

47 We aimed to identify the MCID for the CAT using anchor-based and distribution-bas

48 lity scale can be used as an estimate of the MCID in HCV, and this value may be used as the basis for

49 retest reliability, and we have provided the MCID estimates for FVC% in SSc-ILD based changes at 12 m

50 effect and determine whether it reaches the MCID.

51 tests), but there is currently no validated MCID for exacerbations.

52 ment Scale (ESAS) (range, 0-90 [best-worst]; MCID, 5.7 points).